Table 1.
Clinical characteristics and administration of chemotherapy in 253 patients with primary resection for colorectal liver metastases
| Variable, statistics | Estimate |
|---|---|
| Age in years, median (range) |
66.1 (22.8, 89.2) |
| Gender male/female ratio |
133/120 |
| Synchronous metastasesa, n (%) |
115 (45.5) |
| Disease-free intervalb in months, median (range) |
4 (-14,131) |
| Resections, n |
253 |
| Hemihepatectomy/lobectomy, n (%) |
117 (46.2) |
| Wedge/segment resections, n (%) |
136 (53.8) |
| Simultaneous radiofrequency ablation, n (%) |
12 (4.7) |
| Two-stage resections, n (%) |
3 (1.2) |
| Simultaneous colorectal cancer surgery, n (%) |
14 (5.5) |
| Extent of resection margin in mm, median (range) |
4 (0-50) |
| Number of metastases, median (range) |
2 (1, 12) |
| Metastases diameter in cm, median (range) |
3.0 (0.2,15.0) |
| Bilobar metastases, n (%) |
94 (37.2) |
| Number of resections/patient (1/2/3/4/5) |
203/36/11/2/1 |
| In-hospital mortality, n (%) |
4 (1.6) |
| Follow-up survivors in years, median (range) |
4.7 (1.9-12.9) |
| Chemotherapy preoperatively, n (%) |
88 (34.8) |
| Downstaging, n (%) |
40 (15.8) |
| Perioperativec, n (%) |
43 (17.0) |
| Adjuvant after colon surgery, n (%) |
5 (2.0) |
| Type of chemotherapy |
|
| FOLFOXd, n (%) |
71 (81.6) |
| FOLFIRIe/+bevacizumab, n (%) |
8/3 (9.1/3.4) |
| FOLFIRI + cetuximab, n (%) |
1 (1.1) |
| FLVf, n (%) |
3 (3.4) |
| Other combinations, n (%) |
5 (5.7) |
| Outcome of chemotherapyg (RECIST) |
|
| Partial response, n (%) |
52 (59.1) |
| Stable disease, n (%) |
32 (36.4) |
| Progression, n (%) |
2 (2.3) |
| Unknown, n (%) |
2 (2.3) |
| Number of cycles |
|
| ≤3 |
11 (12.5) |
| 4-6 |
40 (45.4) |
| 7-12 |
27 (30.7) |
| >12 |
7 (8.0) |
| Unknown |
3 (3.4) |
| Chemotherapy adjuvant, n (%) |
44 (17.4) |
| After neoadjuvant, n (%) |
30 (11.9) |
| After downstaging, n (%) |
7 (2.8) |
| Without preoperative chemotherapy, n (%) | 7 (2.8) |
aSynchronous metastases: detected <1 month after surgery of primary colorectal tumor; bdisease-free interval: time from resection of primary colorectal tumor to detection of hepatic metastases; call patients were offered the FOLFOX regimen; dFOLFOX (oxaliplatin, 5-fluorouracil, leukovorin); eFOLFIRI (irinotecan, 5-fluorouracil, leukovorin); fFLV (5-fluorouracil, leukovorin); gRECIST-criteria measured by computed tomography scan.